Andros Pharmaceuticals Co., Ltd.
- Biotech or pharma, therapeutic R&D
Andros Pharma engaged in developing topical new dosage form and super generics with an in-house PICs/GMP facility. Two assets are currently in clinical stage. We are looking for strategic partnerships and collaborative licensing opportunities.
Topical New Dosage Form (Pain Management):
1. APC101 – Topical spray is indicated for Post-herpetic neuralgia (PHN). Finished Phase I (in TW) and Phase II (in AU). Phase III is ready to submit to FDA (in US&AU) in Q2-Q3,2025.
2. APC201 – Topical foam is indicated for Osteoarthritis of the knee (OA). Phase II study will be completed in Q2,2025 (in AU) . Phase I (in AU) was completed in 2024.
3. APC501 is a combination of two local anesthetics. Currently in preclinical phase and is ready for Phase I/IIa in Q4, 2025.
4 super generic products were launched to the market. LTC cream, LALP cream, iMinos solution, LipoT4N5. Please refer to company assets for more details.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}